On January 30, 2026, vTv Therapeutics Inc. announced a new License Agreement amendment with Newsoara Biopharma, granting global rights to their drug HPP737 for a $20 million upfront payment, plus potential earnings of $115 million in milestones. This agreement is significant as it expands market access for the company's product.